Skip to main content
Signal8

Vanda Pharmaceuticals Inc. (VNDA) Form 8-K — Nov 20, 2026

$VNDAForm 8-KItems 1.01, 9.01Filed Nov 20, 2026, 7:05 AM ET0001628280-26-075166Original filing

Vanda Pharmaceuticals settled its patent infringement litigation against MSN Pharmaceuticals over HETLIOZ LQ (tasimelteon suspension), dismissing the Delaware District Court case and granting MSN a non-exclusive, royalty-free license to market its generic in the U.S. The license takes effect in the first quarter of 2040, giving Vanda roughly 13 more years of exclusivity, though MSN can enter earlier if the licensed patents expire or are invalidated, an authorized or licensed generic launches, or unlicensed third-party generics launch unchallenged. MSN gains 180-day pre-launch manufacturing rights and limited pre-launch commercial discussions.

Key figures

License effective date
first quarter of 2040
Pricing contracting lead days
14
Customer discussions lead days
30
Pre launch manufacturing lead time days
180

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Vanda Pharmaceuticals Inc. (VNDA) Form 8-K — Nov 20, 2026: AI Analysis | Signal8